Despite advances in radiation therapy (RT) techniques for the treatment of head and neck cancers, patients with head and neck cancers continue to be at risk of oral and dental complications after surgery or RT because of treatment-induced xerostomia and salivary gland dysfunction, which are associated with increased dental caries.

This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.

It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.

ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.

The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.

Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions.

Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.

The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.

It is important for practitioners to understand what factors influence successful stem cell mobilization in preparation for a transplant. They should also be familiar with the agents used in this process.

Oncology pharmacists are vital members of the oncology team with specialized knowledge of anticancer therapy and can help navigate therapeutic interventions, contributing to selection, dosing, monitoring, evaluation, and education of medications to improve oral immune-related adverse event outcomes.